PAOLI, Pa. & SAN DIEGO--(BUSINESS WIRE)--RODES, Inc. and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announce the signing of exclusive global license and supply agreements for three Captisol-enabled™ (CE) programs. Under the terms of the agreements, for each program Ligand will be eligible to receive development and commercial milestone payments, revenue from the sales of Captisol®, and royalties of 8% to 11% on future net sales. RODES will be responsible for all costs related to the development and commercialization of the programs.
